Zangani Investor Community Announces ViRexxs OvaRex® MAb Coverage
Summary
They provide clients with an array of investor relations products, including customized company strategies, community forums, and webcasting which are tailored for small cap budgets.These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission.ViRexxs most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors.ViRexxs lead product candidate, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexxs licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation.They provide clients with an array of investor relations products, including customized company strategies, community forums, and webcasting which are tailored for small cap budgets.These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission.